Baricitinib Curative Repression of HIV-1
Baricitinib Curative Repression of HIV-1
Not yet recruiting · NCT07209267 · Registry updated 2026-08-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Baricitinib Curative Repression of HIV-1 | Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Not yet recruiting | Phase 2 | 2026-08-17 | NCT07209267 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| Emory University | 393 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dr. Gavegnano's Laboratory | Atlanta | United States | 1 |
| Grady Infectious Diseases Clinic (Ponce Center) | Atlanta | United States | 1 |